BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32120064)

  • 1. The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.
    Alaeikhanehshir S; Engelhardt EG; van Duijnhoven FH; van Seijen M; Bhairosing PA; Pinto D; Collyar D; Sawyer E; Hwang SE; Thompson AM; Wesseling J; Lips EH; Schmidt MK;
    Breast; 2020 Apr; 50():95-103. PubMed ID: 32120064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
    Pilewskie M; Olcese C; Patil S; Van Zee KJ
    Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Survival Outcomes of 'Low Risk' Ductal Carcinoma in situ from a Territory-wide Cancer Registry.
    Co M; Ngan RKC; Mang OWK; Tam AHP; Wong KH; Kwong A
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):40-45. PubMed ID: 32713775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should low-risk DCIS lose the cancer label? An evidence review.
    Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
    Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative radiotherapy after DCIS: Useful for whom?
    Karlsson P
    Breast; 2017 Aug; 34 Suppl 1():S43-S46. PubMed ID: 28663003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
    Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
    Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).
    Cheung S; Booth ME; Kearins O; Dodwell D
    Breast; 2014 Dec; 23(6):807-11. PubMed ID: 25270228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Sopik V; Iqbal J; Sun P; Narod SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):385-93. PubMed ID: 27383477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
    Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.
    Mullooly M; Withrow DR; Curtis RE; Fan S; Liao LM; Pfeiffer RM; de González AB; Gierach GL
    Breast Cancer Res Treat; 2020 Jan; 179(2):445-457. PubMed ID: 31625031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
    Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
    Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
    Partridge A; Adloff K; Blood E; Dees EC; Kaelin C; Golshan M; Ligibel J; de Moor JS; Weeks J; Emmons K; Winer E
    J Natl Cancer Inst; 2008 Feb; 100(4):243-51. PubMed ID: 18270338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
    Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
    Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
    Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort.
    Puvanesarajah S; Gapstur SM; Gansler T; Sherman ME; Patel AV; Gaudet MM
    Cancer Causes Control; 2020 Jan; 31(1):95-103. PubMed ID: 31802322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.